PTC Therapeutics, Inc.

313 articles with PTC Therapeutics, Inc.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on August 6, 2018

  8/10/2018

  PTC Therapeutics, Inc. announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.

• PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update

  8/7/2018

  Entered into agreement to acquire Agilis Biotherapeutics

• Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

  8/2/2018

  PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea

• PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results

  7/26/2018

  PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7, 2018 at 4:30 p.m. (ET) after closing of the market.

• PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort

  7/24/2018

  Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve

• 

  PTC Therapeutics to Buy Agilis Biotherapeutics in Deal that Could Exceed $945 Million

  7/20/2018

  PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.

• PTC Therapeutics to Acquire Agilis Biotherapeutics

  7/19/2018

  PTC Therapeutics, Inc., today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.

• PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy

  7/9/2018

  Translarna is the only approved treatment to address the underlying cause of nmDMD, a rare, genetic, muscle-wasting disease,1 and is currently licensed in Europe for ambulatory patients aged five years and older.3

• 

  PTC Therapeutics Presented Updated Interim Data from SMA Clinical Trial

  6/18/2018

  PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.

• Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference

  6/16/2018

  risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Announced June 7, 2018

  6/8/2018

  PTC Therapeutics, Inc. announced that on June 7, 2018 it approved non-statutory stock options to purchase an aggregate of 134,450 shares of its common stock to 18 new employees and a restricted stock unit for 3,000 shares of its common stock to one of the new employees.

• 

  Shuttered, Closed, Halted and Killed: Biopharma Companies End Programs

  6/5/2018

  BioSpace takes a look at some notable programs that have been shuttered so far this year.

• CHMP Adopts Positive Opinion for the Expansion of the Translarna™ (ataluren) Label to Include Patients as Young as 2 Years of Age

  6/1/2018

  European Commission ratification anticipated in coming months

• PTC Therapeutics to Host Conference Call to Discuss First Quarter 2018 Financial Results

  5/1/2018

  PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its first quarter 2018 financial results and provide an update on the company's business and outlook on Wednesday, May 9, 2018 at 4:30 p.m. (ET) after closing of the market.

• PTC Therapeutics to Participate at Upcoming Investor Conference

  4/30/2018

  PTC Therapeutics, Inc. announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Approved April 24, 2018

  4/27/2018

  PTC Therapeutics, Inc. announced that on April 24, 2018 it approved non-statutory stock options to purchase an aggregate of 172,150 shares of its common stock to 25 new employees and a restricted stock unit for 4,000 shares of its common stock to one of the new employees.

• PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs

  4/9/2018

  PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the Company's commercial products, scientific platforms and R&D programs

• PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease

  4/4/2018

  The program is optimizing small-molecule compounds--identified using PTC's splicing technology platform--that decrease the production of huntingtin protein.

• PTC Therapeutics Announces Pricing of Public Offering of Common Stock

  3/29/2018

  PTC Therapeutics, Inc. announced the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts.

• PTC Therapeutics Announces Proposed Public Offering of Common Stock

  3/27/2018

  PTC Therapeutics, Inc. announced that it is commencing a public offering of 4,000,000 shares of its common stock.